Join        Login             Stock Quote

Exelixis (EXEL): FDA OKs Cometriq for Thyroid Cancer Treatment

 November 30, 2012 01:11 PM

(By Balachander) Exelixis Inc.'s (NASDAQ: EXEL) new drug to treat a rare form of thyroid cancer has been approved by the U.S. Food and Drug Administration (FDA).

The health regulator gave clearance for Exelixis' Cometriq capsule, formerly known as cabozantinib, to treat medullary thyroid cancer (MTC) that has spread to other parts of the body.

"Prior to today's approval and the approval of Caprelsa in April 2011, patients with this rare and difficult to treat disease had limited therapeutic treatment options," the FDA said on Thursday.

In April 2011, the FDA cleared Caprelsa from AstraZeneca Plc (NYSE: AZN) to treat the same condition.

[Related -4 Biotech Stocks Ready To Explode]

The COMETRIQ approval is based on the results of EXAM, a randomized phase 3 clinical trial conducted in 330 patients with progressive, metastatic MTC, which met its primary efficacy endpoint of improving progression-free survival (PFS).

South San Francisco, California-based Exelixis' Cometriq extended PFS for patients in a late-stage study to 11.2 months versus four months for patients receiving a placebo, the FDA noted.

Results also showed that 27 percent of patients treated with Cometriq had reductions in tumor size lasting an average of nearly 15 months, while patients who received a placebo saw no reductions.

Cometriq also received orphan-product designation by the FDA because it is intended to treat a rare disease or condition.

According to the FDA, the most common side effects were diarrhea; inflammation or sores of the mouth; redness, pain, or swelling of the digits (hand-foot syndrome); weight loss, among others.

[Related -Comeback In The Afternoon]

MTC develops in cells in the thyroid gland that make a hormone called calcitonin, which helps maintain a healthy level of calcium in the blood. This type of cancer may occur spontaneously or in families with certain genetic mutations that result in one or more cancers of the endocrine system, including the thyroid gland.

The National Cancer Institute estimates that 56,460 Americans will be diagnosed with thyroid cancer and 1,780 will die from the disease in 2012. About 4 percent of thyroid cancers are medullary thyroid cancer, making it one of the rarer types of thyroid cancers.

Shares of EXEL plunged 7.73 percent to trade at $4.84 on Friday. Over the past year, the stock has been trading between $4.05 and $6.95.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageEmerging-Markets Stocks Took The Lead Last Week

Emerging-markets equities enjoyed a solid rise last week among the major asset classes, based on a set of read on...

article imageDoes Your Latest Investment Pass This Test?

On Wednesday, I sounded the alarm about the problems looming for some consumer staples stocks. In short, read on...

article imageIs The Slump In US Manufacturing Easing?

Yesterday’s November survey data from the Philadelphia Fed hints at the possibility that a stronger trend read on...

article imageMarket Potentially Facing Near Term Technical Headwinds

After the S&P 500 Index pullback on Thursday and Friday last week, the market's advance on Monday and read on...

Popular Articles

Daily Sector Scan
Partner Center

Related Articles:

Winners Of ASCO 2012
More Articles on: Finance , Medical

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.